Iterative Health

We’re hiring: Regional Director, Sites (GI Clinical Research) 📍Northeast, USA At Iterative Health, we’re building a new model for clinical research — embedding studies directly into clinical care and powering sites with AI-enabled tools and services to accelerate new therapies to market. We’re looking for a strategic, operational leader to join our growing team. In this role, you’ll oversee performance across a portfolio of GI-focused clinical research sites, partnering closely with site teams and investigators to drive enrollment, data quality, and operational excellence. This is a highly collaborative, high-impact position at the intersection of clinical operations, strategy, and team leadership. You’ll be a great fit if you bring: • Deep experience in clinical research operations and site management • A strong track record of leading multi-site teams and driving performance • Expertise across trial execution, from startup through enrollment and delivery • A data-driven mindset with the ability to identify trends and implement improvements • Excellent communication skills and the ability to influence across stakeholders • A passion for building high-performing teams and improving patient access to trials This role offers the opportunity to shape site strategy, scale a high-performing research network, and directly impact how quickly innovative GI and hepatology therapies reach patients. If you’re excited about transforming clinical research through technology, leadership, and collaboration, we’d love to hear from you. To apply, visit: https://lnkd.in/g2GJqgE3 To learn more about Iterative Health, visit: http://iterative.health

Congratulations to Jonathan Ng and the entire team at Iterative Health! "Clinical trials are critical in bridging scientific discovery and patient care; however, systematic challenges delay the delivery of new therapies to patients who need them most. More than half of research sites enroll one or fewer patients per study, and nearly 90% of US-based trials fail to meet enrollment targets on time, underscoring the constraints on sites operating in an increasingly complex research environment. Iterative Health is addressing these challenges by building a high-performing, multispecialty clinical research network that embeds research directly into clinical care. Unique from traditional research networks, the company places site success at the center of trial execution. By combining centralized operations, expert staffing, proprietary AI technology, and deep clinical trial expertise, Iterative Health developed a proven site-serving model for sustained site success and reliable trial execution. Sponsors and CROs gain centralized access to industry-leading sites and diverse patient populations, accelerating trials to advance the future of care." Read the full press release here: https://lnkd.in/gWYPUBag cc: Kimberly Baker

Insane that I get to work with healthcare heroes in Krishna Yeshwant and Anthony Philippakis at GV (Google Ventures). Been a student of their work from Day 1 landing in the US 8 years ago, constantly in awe of what it looks like to move big needles in healthcare. And now having the privilege of learning and working directly with them. Let’s build this.

Iterative Health announced a $77 million Series C financing round led by Intrepid Growth Partners and GV (Google Ventures), with participation from Insight Partners, Obvious Ventures, EDBI Pte Ltd (arm of SG Growth Capital, the investment platform of EDB and Enterprise Singapore), and a prominent family office.   Our high-performing, multispecialty clinical research network spans 100+ research sites across North America, Europe, India, and Australia embedded directly into clinical care. Unlike traditional networks, we place site success at the center of trial execution by combining centralized operations, expert staffing, proprietary AI, and deep clinical expertise to drive reliable results for sponsors and CROs. Our trial performance speaks for itself: 2x faster site activation, up to 3 months shorter startup timelines, and 3x higher patient enrollment rates compared to industry benchmarks. The new funding will support expansion into new therapeutic areas beyond GI, hepatology, obesity, cardiology and deepen geographical growth. Jonathan Ng, Founder and CEO, shared: “Every delay in a clinical trial is a delay for patients whose outcomes depend on faster access to innovation. By keeping our physician partners and their patients at the center of our model, we’ve built a system that delivers high-performance site execution at scale. We are excited to bring greater scale to our model in a variety of new therapeutic areas together.” As part of the financing, Ajay Agrawal, Co-Founder and Partner at Intrepid Growth Partners, will join Iterative Health's Board of Directors. Anthony Philippakis, General Partner at GV (Google Ventures), will join as a board observer. We are grateful for the support of our investors and partners as we continue to scale a model designed to accelerate clinical research and improve patient outcomes worldwide. Read the full press release to learn more: https://lnkd.in/gWYPUBag

Tomorrow evening, Iterative Health is sponsoring the West Suburban Gut Club’s Annual GI Chief and Fellows Forum titled: Success in GI/Hepatology & Predictions for GI in the Years to Come. Thank you to the founder and Chairman, Rockford Yapp, MD, for the invite to sponsor this educational event.   This important gathering of GI and liver leaders, and fellows from across the country, serves as a premier forum for advancing dialogue in gastroenterology and hepatology. As the field continues to evolve, this meeting provides a unique opportunity to bring together leading clinicians, researchers, and fellows to share perspectives, mentor the next generation, and discuss the future of GI and liver care. We are pleased to support initiatives like the GI Chief and Fellows Forum that strengthen education, collaboration, and innovation across the GI community. To learn more about Iterative Health’s work in advancing clinical research in GI and liver disease, visit: http://iterative.health

Catch us at these conferences in May! We’re excited to attend a mix of leading GI, hepatology, and clinical research conferences in the coming weeks. Message a team member to set up a time to connect! DDW (Digestive Disease Week) 📆 May 2–5 | 📍Chicago, IL Sponsors reach out to Laura Mantell  Providers reach out to Jody Bare to set up a meeting! European Congress on Obesity 📆 May 12–15 | 📍Maastricht, Netherlands Reach out to Mario Gutierrez Casale MD. MPH. to set up a meeting! EASL Congress 📆 May 27–30 | 📍Barcelona, Spain Reach out to Mario Gutierrez Casale MD. MPH. to set up a meeting! Don’t miss the chance to meet us in person and discuss how we can partner to accelerate research to bring life-changing therapies to patients sooner. To learn more about Iterative Health, visit http://iterative.health

We’re hiring: Senior Clinical Research Specialist (Cardiology) 📍 Cambridge, MA or New York, NY At Iterative Health, we’re building a new model for clinical research — embedding studies directly into clinical care and powering sites with AI-enabled tools and services to accelerate new therapies to market. We’re looking for an experienced clinical research professional to join our growing cardiology team. In this role, you’ll work directly with research sites across the U.S., helping them optimize workflows, adopt new technologies, and deliver high-quality clinical trials. This is a highly collaborative, external-facing position with real impact on how quickly innovative therapies reach patients. You’ll be a great fit if you bring: • Deep experience in clinical research (CRC background strongly preferred) • Expertise across trial execution—from startup to enrollment and beyond • A passion for improving site performance and patient access to trials • Comfort working with new technologies and data-driven tools • Strong communication skills and a consultative mindset This role offers the opportunity to partner closely with leading cardiology sites, shape best practices, and help scale a high-performing research network. If you’re excited about transforming clinical research through technology and collaboration, we’d love to hear from you. To learn more and apply, visit: https://lnkd.in/ghzvvQWK

The MASH treatment landscape is evolving quickly, and so are the decisions clinicians face. In this video from the Chronic Liver Disease Foundation, Iterative Health’s Chief Medical Officer of Hepatology & Obesity, Dr. Nadege Gunn, MD, CPI, DABOM, FAASLD, highlights both the progress and the gaps that remain: “This is revolutionary for our patients living with MASH, a disease that has not had a treatment up until recently, so we have options to offer our patients. But again, we know there are still unmet needs because these medications right now are targeting F2 and F3 fibrosis.” As new therapies emerge, the opportunity—and responsibility—is clear: expand impact beyond a subset of patients through earlier identification, personalized care, and continued innovation. A clear reminder that advancing care in MASH means reaching patients across every stage of disease. To learn more about our work in Hepatology & Obesity clinical research, visit: http://iterative.health

This past Saturday at Obesity Medicine 2026, Iterative Health’s Chief Medical Officer of Hepatology & Obesity, Dr. Nadege Gunn, MD, CPI, DABOM, FAASLD, spoke as a leading expert in Obesity and MASLD during an innovation symposium. The non—CME session, sponsored by Boehringer Ingelheim as part of their commitment to advancing education on the interconnected nature of metabolic diseases, was titled Undertreated and Underdiagnosed: Bridging the Epidemics of Obesity and MASLD. It highlighted why the industry must shift its approach to comprehensive obesity care. A few key takeaways from the presentation: The MASLD/MASH Connection: The multifaceted nature of obesity and how it exponentially increases the risk for related liver conditions. The Power of Early Action: The critical need for early identification, diagnosis, and management to ensure the best patient outcomes. Front-Line Impact: The vital role front-line clinicians play in proactive screening and comprehensive care planning. We are incredibly proud of Dr. Gunn’s ongoing leadership and her dedication to advancing the standard of care in hepatology and obesity medicine. In her role as Chief Medical Officer, Hepatology & Obesity, Dr. Gunn oversees medical affairs, development of specialized site operations, and strategic collaboration with sponsors. To learn more about our work in Hepatology & Obesity clinical research, visit: http://iterative.health

Bringing a new therapy to market can take over a decade and billions of dollars, but the biggest challenges often come down to execution. As Iterative Health’s Chief Operating Officer, Dana Feuchtbaum sees this firsthand. Clinical trials require constant coordination across sponsors, research sites, clinicians, and patients, and every delay can slow the path to care while driving up costs. “Every day that a drug remains in development instead of on the market costs millions of dollars, making efficient trials essential to recoup investment and fund ongoing research that advances patient care,” Dana explains in a recent article with HealthCentral. That’s why Iterative Health empowers high-performing research sites with specialized operations, staffing, and technology delivering industry-leading speed and enrollments so promising therapies reach patients faster Read Dana’s full insights in her HealthCentral feature: https://lnkd.in/gpSrX_gT To learn more about how Iterative Health partners with sponsors to accelerate clinical trials and bring therapies to patients faster, visit: https://lnkd.in/eGv4sxdR